WO2011117362A1 - Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells - Google Patents

Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells Download PDF

Info

Publication number
WO2011117362A1
WO2011117362A1 PCT/EP2011/054561 EP2011054561W WO2011117362A1 WO 2011117362 A1 WO2011117362 A1 WO 2011117362A1 EP 2011054561 W EP2011054561 W EP 2011054561W WO 2011117362 A1 WO2011117362 A1 WO 2011117362A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
veterinary
acceptable salt
salt
Prior art date
Application number
PCT/EP2011/054561
Other languages
French (fr)
Inventor
Sergio Pumarola Segura
Josep Lluis TORRES SIMÓN
Original Assignee
Bioglane, S.L.N.E.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglane, S.L.N.E. filed Critical Bioglane, S.L.N.E.
Priority to MX2012010988A priority Critical patent/MX2012010988A/en
Priority to PL11710197T priority patent/PL2549994T3/en
Priority to EP11710197.2A priority patent/EP2549994B1/en
Priority to US13/636,155 priority patent/US9226517B2/en
Priority to DK11710197.2T priority patent/DK2549994T3/en
Priority to ES11710197.2T priority patent/ES2551408T3/en
Priority to CN2011800154714A priority patent/CN102811720A/en
Publication of WO2011117362A1 publication Critical patent/WO2011117362A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/38—Diluting, dispersing or mixing samples
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • iminocvclitols as inhibitors of bacterial adherence to epithelial cells
  • the present invention relates to the use of iminocyclitols in the prevention and/or coadjuvant treatment of bacterial infections or microflora imbalances, as well as to pharmaceutical, veterinary, or food compositions containing them.
  • Bacterial adherence to mucosal surfaces is considered to be an important prerequisite for colonization and infection.
  • the first type of adhesive interaction is due to the binding of lectins with carbohydrate structures.
  • the second type involves recognition between a protein on the bacterium and a complementary protein on the mucosal surface.
  • the third type comprises the binding interactions that occur between hydrophobins, frequently involving hydrophobic moieties of proteins interacting with lipids.
  • the first type, the lectin adhesins are usually classified by sugar specifity. Specifity can be determined by inhibiting the adhesion with either simple or complex carbohydrates that compete with the binding of the adhesins to host cells.
  • inhibitors are iminocyclitols also called iminosugars or azasugars.
  • iminocyclitols also called iminosugars or azasugars.
  • DNJ is a glucosidase inhibitor.
  • these glucosidase inhibitors often cause intestinal discomfort and diarrhoea.
  • the patent application US20090087501 provides an oral composition having at least two botanical active ingredients derived from plants.
  • the botanical active ingredients provide particularly efficacious antimicrobial, antioxidant, anti inflammatory, antiageing and/or healing properties to the oral
  • the Japanese patent application JP19920073844 describes a toothpaste comprises an extract of Kuwahakubi and an extract of Moms Alba.
  • immunostimulant comprises water soluble extract of bark of mulberry, as an active ingredient.
  • the document Asano et al. "N-containing sugars from Moms Alba and their glycosidase inhibitory activities" Carbohydrate Research 1994, vol. 259. pp. 243-255, describes the N-containing sugars from the roots of Morus Alba, and the glycosidase inhibitory activities of these compounds.
  • the patent application WO2009152665 describes a pharmaceutical composition comprises fagomine for treating and preventing diabetes.
  • the patent application WO2010029313 describes alkaloids and imino sugars with activity against HCV (Hepatitis C virus) and RSV ( respiratory syncytial virus).
  • the patent application WO03002127 describes the use of a glycoinhibitor substance comprising a pyranose structure with at least one oligosaccharide for treatment an infectious disease.
  • the patent application EP0852948 describes the use of inhibitors of glycosidase enzymes, such as a-galactosidase, in the treatment of malaria, endotoxic shock and septic shock. The inhibitors reduce the conversion of the toxin precursor to toxin, thereby reducing the amount of toxin circulating in malaria patients.
  • D-fagomine and its alkylated derivatives inhibit the bacterial adherence to epithelial cells which makes these compounds useful for the prevention and/or coadjuvant treatment of infections caused by an enteric, oral or respiratory bacteria. They are advantageous since with concentrations of ppm contribute in preventing and/or treating bacterial infections, without producing side effects.
  • D-fagomine (2R, 3R, 4R)-2-hydroxymethylpiperidine-3,4-diol is a natural iminocyclitol, a polyhydroxylated piperidine which was first isolated from buckwheat seeds of Faqopyrum esculentum moench and later from
  • D-fagomine or its alkylated derivatives or its salts have the ability of inhibiting the adherence to epithelial cells of pathogen bacteria, and its practical value in the prevention and/or in the coadjuvant treatment of diseases where bacterial adherence is a prerequisite for the initiation of infection.
  • inhibition of the adherence to epithelial cells of pathogen bacteria is meant to reduce contact between the receptors on the surface on the epithelial cells and the binding entity originated in the bacterium, the adhesins, specifically lectins, thereby preventing adhesion of the infectious agent. Since a better adherence enables bacterial survival; prevention of adhesion at an early stage, prevents the infection.
  • adherence to epithelial cells of enteric, oral and respiratory bacteria is required for colonization and that colonization is required for subsequent development of symtoms of diseases, Ofek et al. , “Bacterial adhesion to animal cells and tissues", ASM Press 2003, chapter 1 .
  • the inhibition not only prevent that the infection occurs but also is a useful coadjuvant for treating the infection.
  • the adhesion mechanism is a process with multiple steps. It has been suggested that there are two distint kinetic steps, the first of which is readily reversible. Once the second step has taken place, the cell becomes firmly bound and the binding is only very slowly reversible.Therefore the first step of the adhesion mechanism can be reversible in the case that the adhesins of the bacteria has greater affinity for the antiadhesion agent and at a first step the bacterial infection can be treated.
  • an aspect of the present invention relates to a compound of formula (I) or a pharmaceutically, veterinary or edible acceptable salt thereof, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof,
  • R-i , R 2 , R3, R 4 is independently selected from the group consisting of H, (C-i-C-n)-alkyl, and CH 2 Ph, for use in the prevention and /or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above, together with pharmaceutical excipients or carriers.
  • a veterinary composition comprising a compound of formula (I) or a veterinary acceptable salt thereof or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a veterinary acceptable salt thereof as defined above, together with veterinary excipients or carriers.
  • the compounds of the invention help to improve gut flora by inhibiting the growth of harmful bacteria, for example Escherichia coli, but without inhibiting the beneficial bacteria, for example Lactobacilli and
  • Bifidobacteria This is because these compounds inhibit the bacterial adherence to epithelial cells in a selective form.
  • the presence of the compounds of the invention in the animal feed is associated with a decreased incidence of infectious diseases, and increased weight gain also called "growth promoting effect", this is because the compounds of the invention adhere to harmful bacterium, but not healthy bacteria, for example Lactobacillus or Bifidobacterium and other useful probiotics.
  • D-fagomine and the alkylated derivatives as part of a nutritional composition food and feedstuff.
  • This said functional food has a positive effect on the person's or animal's health by preventing bacterial infection caused by an enteric, oral or respiratory bacteria.
  • composition pet food or feed composition
  • the compounds of the invention may be used alone or in combination with other suitable bioactive compounds or probiotics.
  • compounds of formula (I) or their salts can be used in prevention and /or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria, administered alone or in combination with a saccharide, iminocyclitol, probiotics or antibacterial agent.
  • another aspect of the present invention relates to a combination of a compound of formula (I) or their salts or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof as defined above, with a saccharide, a iminocyclitol, probiotic or an antibacterial agent, for the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria.
  • Another aspect of the present invention relates to a pharmaceutical composition, comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above, with a saccharide, a iminocyclitol, probiotic or an antibacterial agent, together with pharmaceutical excipients or carriers.
  • Another aspect of the present invention relates to a veterinary composition, comprising a compound of formula (I) or their veterinary acceptable salts or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a veterinary acceptable salt thereof as defined above, with a saccharide, a iminocyclitol, probiotic or an antibacterial agent, together with veterinary excipients or carriers.
  • a food, pet food or feed composition comprising a combination of a compound of formula (I) or their appropriate edible acceptable salts or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a edible acceptable salt thereof as defined above, with a saccharide, iminocyclitol or a probiotic.
  • an aspect of the present invention relates to compounds of formula (I) or their pharmaceutically, veterinary or appropriate edible acceptable salts, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria.
  • R-i , R 2 , R 3 , and R 4 are H.
  • This aspect of the invention can also be formulated as use of a compound of formula (I) or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or their salts as defined above, for the preparation of a pharmaceutical or a veterinary composition, for the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria in a mammal, including a human.
  • the invention also relates to a method of coadjuvant treatment and/or prophylasis of a mammal, including a human, suffering from or being susceptible to a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria, said method comprising the administration to said mammal, including a human of an effective amount of the compounds of the present invention or alternatively, an enriched extract of natural origin comprising a compound of formula (I), including the known compounds mentioned above, together with acceptable excipients or carriers.
  • Non-limiting D-fagomine salts which may be used within the scope of the present invention are tartrate, hemitartrate, citrate, hemicitrate, chlorinstae, malate, or acetate salts.
  • the plant extract is an enriched extract in order to be useful.
  • the enriched plant extract comes from a plant selected from the group consisting of Moms Alba, and Faqopyrun esculentum.
  • the plant is
  • enriched extract refers to an extract wherein the amount of active compound is higher than in the natural extract, obtained by physical or chemical methods.
  • therapeutically effective amount refers to the amount of a compound that, when administered, is sufficient to prevent development of, alleviate to some extent, one or more of the symptons of the disorder, disease, microflora imbalance or condition being treated.
  • dose of compound administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and the similar considerations.
  • saccharides epithelial cells receptor analog for example methyl a mannoside, globotetraose, mannose, gal a(1 4) gal o linked methyl, sialyl 3' lactose, sialyl-gal ( ⁇ 1 4)GlcNAc, oxidized( a1 6) glucan.
  • epithelial cells denotes herein to any epithelial cells which cover the external surface of the body as well as the major body cavities.
  • probiotic denotes live microorganisms which, when administered in adequate amounts, confer a health benefit on the host, and it has not modified its adhesion to the intestinal mucosa with the presence of the iminocyclitols.
  • (Ci-Cn)-alkyl denotes herein straight or branched chain alkyl.
  • the D-fagomine for the purposes of the invention can be synthetic or of natural origin, in the form of a plant extract or purified substance.
  • functional food denotes herein any healthy food claimed to have a health-promoting or disease-preventing property beyond the basic function of supplying nutrients.
  • a particular embodiment is the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or repiratory bacteria.
  • the compounds of the invention are used in the prevention of a bacterial infection caused by an enteric, oral or respiratory bacteria.
  • the bacteria are selected from the group consisting of Streptococcus mutans, Salmonella tphimurium, Escherichia coli, Streptococcus mitis, Streptococcus oralis, Streptococcus gordonii,
  • the compounds of the invention are used as coadjuvants in the treatment of a disease caused by the bacterial infection, which s selected from the group consisting of dental caries, periodontal disease, urinary disease, and intestinal disease.
  • the compounds of the invention are for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria, by inhibiting the adherence of enteric, oral or respiratory bacteria to epithelial cells.
  • bacterial adherence is understood the process whereby bacteria attach themselves to cells or other surfaces before proliferating.
  • a pharmaceutical composition or a veterinary veterinary veterinary adherence is understood the process whereby bacteria attach themselves to cells or other surfaces before proliferating.
  • composition comprising the compounds of the invention or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof, together with
  • the pharmaceutical composition is a mouthwash, a gel, a liquid dental cleaning lotion, a tooth paste, a chewing gum, a denture cleaner or a prothesis adherence cream.
  • the pharmaceutical composition is a chewing gum.
  • the compounds of the invention as part of a nutritional composition food, pet food and feedstuff.
  • the said functional food has a positive effect on the person's or animal's health by preventing bacterial infection and microflora imbalances caused by an enteric, oral or respiratory bacteria.
  • Relevant areas of use in feed as a preventive of diseases in animal production are for example salmonellosis in chicken production, harmful microbism reduction in pig to obtain a better growth, or acidosis prevention in ruminants.
  • the compounds of the invention can also be used as a food or a beverage additive to produce a functional food or a functional beverage.
  • they can be added to liquid food products or concentrates or powders, such as milk and liquid milk like products, various beverage including juices, soft drinks, sport drinks, alcoholic beverages, and the like. It is specially useful to have the compound of the invention as part of a food for an infant, preferably as a part of a infant formula.
  • relevant examples could be beer, non-alcohol beer, tea like drink, milk like drink, pasta, biscuits, cookies, cereal bars, swollen grains, bread, crepes, cakes, creams, desserts, breakfast cereals and others that are enriched or
  • the food or food additive can also be produced in a natural way, e.g. by having a domestic animal such a cow or other animal that produce D- fagomine in its milk. This can be accomplished by feeding the animal with Fagopyrum esculentum, Moms alba or purified D-fagomine
  • the compounds of the invention may be used alone or in combination with other suitable bioactive compounds such as a saccharide, a iminocyclitol, probiotics or an antibacterial agent in prevention and /or coadjuvant treatment of a bacterial infection caused by an enteric, oral or respiratory bacteria.
  • suitable bioactive compounds such as a saccharide, a iminocyclitol, probiotics or an antibacterial agent in prevention and /or coadjuvant treatment of a bacterial infection caused by an enteric, oral or respiratory bacteria.
  • Pharmaceutical compositions, veterinary compositions food, pet food and feed products comprising the combination are also part of the invention.
  • the combinations of the invention may be used in the prevention and/or coadjuvant treatment of a bacterial infection caused by enteric, oral or respiratory bacteria.
  • the combinations are used in the prevention and/or coadjuvant treatment of a bacterial infection caused by an enteric, oral or respiratory bacteria by inhibiting the adherence of enteric, oral or respiratory bacteria to epithelial cells.
  • the combination is for sequential, simultaneous or separate administration.
  • Non limiting probiotics which may be used within the scope of the present invention are: Lactobacillus acidophilus, Lactobacillus rhamnosus,
  • Lactobacillus bulgaricus Lactobacillus salivarius, Lactobacillus plantarum,
  • Lactobacillus casei Lactobacillus sporogenes, Bifidobacteria bifidum,
  • Example 1 Bacterial agglutination assay
  • Bacteria used in the assay were Escherichia coli. Salmonella tphimurium and Streptococcus mutans, from over night cultures. The bacteria were inoculated in the 100 ml flask with Luria medium. The bacteria were grown for 24 h at 37°C. After incubation, Agar Luria medium plates were inoculated. After 24h suspensions of each strain were prepared in PBS medium (10 8 CFU/ml).
  • Example 2 Bacterial agglutination assay Bacteria used in the assay were Escherichia coli, Salmonella tphimurium,
  • Streptococcus mutans Lactobacillus casei and Bifidobacterium sp., from over night cultures.
  • the bacteria were inoculated in the 100 ml flask with Luria medium. The bacteria were grown for 24 h at 37°C. After incubation, Agar Luria medium plates were inoculated. After 24h suspensions of each strain were prepared in PBS medium (10 8 CFU/ml). Serial dilutions of the product to be tested, D-fagomine tartrate (10 ppm, 20 ppm, 2000 ppm) were made. The dilutions were mixed with bacterial suspensions in a 1 :1 ratio. After 90 min. at room temperature the suspensions were observed under optical microscope. They were compared with the control culture without any product added. The Escherichia coli and Salmonella tphimurium were compared with a positive control culture (mannose 0,05M).
  • Streptococcus mutans but not at 10ppm.
  • concentration of the product assay is 20ppm
  • the agglutination was about 60% that of the corresponding positive control, and when the concentration is 200ppm was about 70%.
  • Lactobacillus casei, Bifidobacterium sp were not agglutinated by D-fagomine tartrate. When the bacteria are agglutinated they lost their ability to adhere to other cells or substrate.
  • the bacterium used in the assay was Streptococcus mutans from over night cultures (1 10 10 UCF/ml). The bacterium was grown for 18 h at 37°C in PBS medium. The bacteria from the overnight culture (0.25 ml) were grown for 18 h at 4°C in a glass dish with the specific medium (0.5 ml). After the 18 h, 0.25ml of D-fagomine (1 Oppm, 20ppm and 40ppm) was added. In the control plate was added only PBS. After 90 min. the cells were transfered (0.5ml) to a falcon tube, then were washed two times with PBS (0.5 ml each time). The wash of each bacteria was collected in a falcon tube and was kept at 4°C. The cells (100 ⁇ ) were seeded in the plates in TSA medium. The cells adhered were scrapped.
  • PG/CG Product glass/Control glass(without product); colony forming units in glass by the action of D-fagomine or mannose 0.05M / colony forming units in glass without product
  • G/MG Glass/ Mannose glass; colony forming units in glass by the action of D-fagomine or medium / colony forming units in glass by the action of mannose 0.05M
  • Example 4 Adhesion of Salmonella and Escherichia colli to Mucus in D- fagomine presence
  • Mucus mucosal epitelial cells
  • the bacteria was inoculated in the tube, with 3 ml Luria medium. The bacteria were grown for 24 h at 37°C. The tube was incubated overnight (1 10 8 -1 10 9 UCF/ml).
  • the mucus (1 ml) is defrosted at room temperature.
  • PBS medium 100ml was prepared.
  • the defrosted mucus was centrifuged at 8000rpm for 10 minutes.
  • the mucus (1 ml) was transferred to an aliquot with sterile PBS (99 ml) (1 :100). Each well is inoculated with 2,5 ml from the mixture and the plate is kept in the fridge (4°C) overnight.
  • the plate was taken out from the fridge. 2ml was extracted from each well. PBS (1 ml) was added, then was extracted, at the end there was 0.5 ml in the well.
  • the tubes that were grown overnight were diluted (1 10 7 UCF/ml).
  • the final volume in each well was: PBS 0.5 ml plus bacterial suspension 0.5 ml plus D-fagomine 0.5 ml (or PBS in control case).
  • the wells were inoculated and the plates were incubated at 37°C for 90 minutes. After the 90 minutes, the supernatant of each well (1 ⁇ ) were observed under optical microscope.
  • Escherichia coli 2.96 10 8 2.45 10 6 1.21 10 2 2.98 10 8 99.2 2
  • microorganisms are significantly in the supernatant, not in the mucus.
  • D-fagomine the microorganisms are aglutinated between them and they are not agglutinated with the mucus, independently of the D- fagomine concentration.
  • Example 5 Adhesion of Lactobacillus and Bifidobacterium to Mucus in D- fagomine presence
  • the mucus (1 ml) is defrosted at room temperature. 100ml of PBS medium was prepared. The defrosted mucus (1 ml) was centrifuged at 8000rpm for 10 minutes. The mucus (1 ml) was transferred to an aliquot with sterile PBS (99 ml). Each well is inoculated with 2.5 ml from the mixture and the plate is kept in the fridge (4°C) overnight.
  • the plate was taken out from the fridge an the wash was made. 2ml was extracted from each well. PBS (1 ml) was added, then was extracted, at the end there was 0.5 ml in the well.
  • the final volume in each well was: PBS 0.5 ml plus bacterial suspension 0.5 ml plus D-fagomine 0.5 ml (or PBS in control case). It was prepared 2 plates (duplicated strains). Product concentration in the wells (10 ppm, 20 ppm, 40 pppm). Mannose concentration 0.05M ( control well). The wells were inoculated and the plates were incubated at 37°C for 90 minutes. After the 90 minutes, the supernatant of each well (1 ⁇ ) were observed under optical microscope. It was added 1 ml of each well in eppendorfs. The eppendords were kept on the fridge. Two wash were made with PBS.
  • D-fagomine does not interfere negatively the adherence of the Lactobacillus to the mucus. In view of the cultive medium results, the D-fagomine benefits the adherence of Lactobacillus to mucus.
  • D-fagomine does not interfere negatively the adherence of the Bifidobaterium to the mucus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pediatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

It comprises the use of D-fagomine or derivatives thereof in the prevention and/or coadjuvant treatment of bacterial infections, as well as to pharmaceutical, veterinary, or food and feed, pet food compositions containing them.

Description

Use of iminocvclitols as inhibitors of bacterial adherence to epithelial cells
The present invention relates to the use of iminocyclitols in the prevention and/or coadjuvant treatment of bacterial infections or microflora imbalances, as well as to pharmaceutical, veterinary, or food compositions containing them.
BACKGROUND ART Bacterial adherence to mucosal surfaces is considered to be an important prerequisite for colonization and infection. A variety of molecules and macromolecular structures, collectively known as adhesins, binding entity coming from the bacterium, recognized and interact with receptors on the surface on the host cells.
Three principal types of adhesin-receptor interactions have been described. The first type of adhesive interaction is due to the binding of lectins with carbohydrate structures. The second type, of which a significant number of cases are known, involves recognition between a protein on the bacterium and a complementary protein on the mucosal surface. The third type, comprises the binding interactions that occur between hydrophobins, frequently involving hydrophobic moieties of proteins interacting with lipids.
The first type, the lectin adhesins are usually classified by sugar specifity. Specifity can be determined by inhibiting the adhesion with either simple or complex carbohydrates that compete with the binding of the adhesins to host cells.
Sharon et al. in the document "Bacterial adherence to cell surface sugars" , Ciba Found Symp. 1981 , vol.80, pp 1 19-41 , describes that the attachment strains of Escherichia coli and Salmonella spp. to epithelial cells is inhibited by D-mannose. Unfortunately the active mannose concentration necessary to produce inhibition, is high, al least about 0.5 M. Escherichia coli is among the most common causes of diarrhea, to receptors on intestinal epithelial cells. Escherichia coli may colonize, too, the vaginal and periurethral area and ascend the urinary tract. Its adhesion to the epithelial cells is the initial step in the establishment of infection. Thus, the ability to attach to the mucosal surface is thought to be essential for Escherichia coli to colonize and to remain in the urinary tract.
The document, Jose A. Castillo et at "Fructose-6-phosphate aldolase in organic synthesis: preparation of D- Fagomine, N-alkylated derivatives, and preliminary biological assays" Organic Letter 2006, vol. 8, n°26, pp. 6067- 6070, describes that D-fagomine and the N-alkylated derivatives C4, C6, C8 , C9 and Ph-CH2 do not show antimicrobial activity.
Other type of inhibitors are iminocyclitols also called iminosugars or azasugars. The document, Barira Islam et al. "Novel anti-adherence activity of mulberry leaves: Inhibition of Streptococcus mutans biofilm by 1 - deoxynojirimycin isolated from Moms alba", Journal of Antimicrobial
Chemotherapy 2008, vol. 62, pp.751 -757, describes the anti-microbial activity against S. mutans of 1 -deoxynojirimycin, compound isolated from M. alba. DNJ is a glucosidase inhibitor. Unfortunately, these glucosidase inhibitors often cause intestinal discomfort and diarrhoea.
Other botanical extract are described in the following patent applications.
The patent application US20090087501 provides an oral composition having at least two botanical active ingredients derived from plants. The botanical active ingredients provide particularly efficacious antimicrobial, antioxidant, anti inflammatory, antiageing and/or healing properties to the oral
composition.
The Japanese patent application JP19920073844 describes a toothpaste comprises an extract of Kuwahakubi and an extract of Moms Alba.
The Japanese patent application JP20070230719 describes an
immunostimulant comprises water soluble extract of bark of mulberry, as an active ingredient. The document Asano et al. "N-containing sugars from Moms Alba and their glycosidase inhibitory activities" Carbohydrate Research 1994, vol. 259. pp. 243-255, describes the N-containing sugars from the roots of Morus Alba, and the glycosidase inhibitory activities of these compounds.
Finally the patent application CA2696874 describes an effective fraction of alkaloids prepared from mulberry twig, and the pharmaceutical composition containing the effective fraction for preparing hypoglycemic agents. Other documents describe sugars or imino sugars for different
pharmaceutical applications. The patent application WO2009152665 describes a pharmaceutical composition comprises fagomine for treating and preventing diabetes. The patent application WO2010029313 describes alkaloids and imino sugars with activity against HCV (Hepatitis C virus) and RSV ( respiratory syncytial virus). The patent application WO03002127 describes the use of a glycoinhibitor substance comprising a pyranose structure with at least one oligosaccharide for treatment an infectious disease. Finally the patent application EP0852948 describes the use of inhibitors of glycosidase enzymes, such as a-galactosidase, in the treatment of malaria, endotoxic shock and septic shock. The inhibitors reduce the conversion of the toxin precursor to toxin, thereby reducing the amount of toxin circulating in malaria patients.
Thus, from what is known in the art, it is derived that the development of inhibitors of the bacterial adherences is still of great interest.
SUMMARY OF THE INVENTION
Inventors have found that the D-fagomine and its alkylated derivatives inhibit the bacterial adherence to epithelial cells which makes these compounds useful for the prevention and/or coadjuvant treatment of infections caused by an enteric, oral or respiratory bacteria. They are advantageous since with concentrations of ppm contribute in preventing and/or treating bacterial infections, without producing side effects.
D-fagomine (2R, 3R, 4R)-2-hydroxymethylpiperidine-3,4-diol, is a natural iminocyclitol, a polyhydroxylated piperidine which was first isolated from buckwheat seeds of Faqopyrum esculentum moench and later from
Castanospermum australe, dry Xhanthocercis zambesiaca leave and Moms bombvcis leaves. The D-fagomine (2R, 3R, 4R)-2-hydroxymethylpiperidine- 3,4-diol is shows in the formula below.
Figure imgf000005_0001
OH
Nothing in the art suggests that the D-fagomine or its alkylated derivatives or its salts have the ability of inhibiting the adherence to epithelial cells of pathogen bacteria, and its practical value in the prevention and/or in the coadjuvant treatment of diseases where bacterial adherence is a prerequisite for the initiation of infection.
By inhibition of the adherence to epithelial cells of pathogen bacteria is meant to reduce contact between the receptors on the surface on the epithelial cells and the binding entity originated in the bacterium, the adhesins, specifically lectins, thereby preventing adhesion of the infectious agent. Since a better adherence enables bacterial survival; prevention of adhesion at an early stage, prevents the infection. There is compelling evidence showing that adherence to epithelial cells of enteric, oral and respiratory bacteria is required for colonization and that colonization is required for subsequent development of symtoms of diseases, Ofek et al. , "Bacterial adhesion to animal cells and tissues", ASM Press 2003, chapter 1 .
The inhibition not only prevent that the infection occurs but also is a useful coadjuvant for treating the infection. The adhesion mechanism is a process with multiple steps. It has been suggested that there are two distint kinetic steps, the first of which is readily reversible. Once the second step has taken place, the cell becomes firmly bound and the binding is only very slowly reversible.Therefore the first step of the adhesion mechanism can be reversible in the case that the adhesins of the bacteria has greater affinity for the antiadhesion agent and at a first step the bacterial infection can be treated.
Therefore, an aspect of the present invention relates to a compound of formula (I) or a pharmaceutically, veterinary or edible acceptable salt thereof, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof,
Figure imgf000006_0001
OR4
(I) where R-i , R2, R3, R4 is independently selected from the group consisting of H, (C-i-C-n)-alkyl, and CH2Ph, for use in the prevention and /or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria.
Another aspect of the present invention relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above, together with pharmaceutical excipients or carriers. Another aspect of the present invention relates to a veterinary composition comprising a compound of formula (I) or a veterinary acceptable salt thereof or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a veterinary acceptable salt thereof as defined above, together with veterinary excipients or carriers.
The compounds of the invention, particularly D-fagomine, help to improve gut flora by inhibiting the growth of harmful bacteria, for example Escherichia coli, but without inhibiting the beneficial bacteria, for example Lactobacilli and
Bifidobacteria. This is because these compounds inhibit the bacterial adherence to epithelial cells in a selective form. The presence of the compounds of the invention in the animal feed is associated with a decreased incidence of infectious diseases, and increased weight gain also called "growth promoting effect", this is because the compounds of the invention adhere to harmful bacterium, but not healthy bacteria, for example Lactobacillus or Bifidobacterium and other useful probiotics.
Therefore, it is possible to use D-fagomine and the alkylated derivatives as part of a nutritional composition food and feedstuff. This said functional food has a positive effect on the person's or animal's health by preventing bacterial infection caused by an enteric, oral or respiratory bacteria.
Therefore another aspect of the present invention relates to a food
composition, pet food or feed composition comprising a compound of formula (I) or a appropriate edible salt thereof or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a edible acceptable salt thereof as defined above.
Most bacteria posses genes encoding more than one type of adhesin, a phenomenon that would require the use of multiple agents for multiple adhesins. Thus, the compounds of the invention may be used alone or in combination with other suitable bioactive compounds or probiotics. In a particular embodiment, compounds of formula (I) or their salts can be used in prevention and /or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria, administered alone or in combination with a saccharide, iminocyclitol, probiotics or antibacterial agent.
Therefore, another aspect of the present invention relates to a combination of a compound of formula (I) or their salts or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof as defined above, with a saccharide, a iminocyclitol, probiotic or an antibacterial agent, for the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria.
Another aspect of the present invention relates to a pharmaceutical composition, comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above, with a saccharide, a iminocyclitol, probiotic or an antibacterial agent, together with pharmaceutical excipients or carriers.
Another aspect of the present invention relates to a veterinary composition, comprising a compound of formula (I) or their veterinary acceptable salts or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a veterinary acceptable salt thereof as defined above, with a saccharide, a iminocyclitol, probiotic or an antibacterial agent, together with veterinary excipients or carriers.
Therefore another aspect of the present invention relates to a food, pet food or feed composition comprising a combination of a compound of formula (I) or their appropriate edible acceptable salts or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a edible acceptable salt thereof as defined above, with a saccharide, iminocyclitol or a probiotic.
It also forms part of the invention the compounds of formula (I) or their salts as defined above, for use as inhibiting agent of the adherence of enteric, oral or respiratory bacteria to epithelial cells.
DETAILED DESCRIPTION OF THE INVENTION As mentioned above, an aspect of the present invention relates to compounds of formula (I) or their pharmaceutically, veterinary or appropriate edible acceptable salts, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria. In a preferably embodiment R-i , R2, R3, and R4 are H.
This aspect of the invention can also be formulated as use of a compound of formula (I) or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or their salts as defined above, for the preparation of a pharmaceutical or a veterinary composition, for the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria in a mammal, including a human. The invention also relates to a method of coadjuvant treatment and/or prophylasis of a mammal, including a human, suffering from or being susceptible to a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria, said method comprising the administration to said mammal, including a human of an effective amount of the compounds of the present invention or alternatively, an enriched extract of natural origin comprising a compound of formula (I), including the known compounds mentioned above, together with acceptable excipients or carriers. Non-limiting D-fagomine salts which may be used within the scope of the present invention are tartrate, hemitartrate, citrate, hemicitrate, chlorhidrate, malate, or acetate salts. Because the D-fagomine occurs naturally in small amounts, preferably the plant extract is an enriched extract in order to be useful. Generally, the enriched plant extract comes from a plant selected from the group consisting of Moms Alba, and Faqopyrun esculentum. Preferably, the plant is
Faqopyrum esculentum.
The term "enriched extract" as used herein, refers to an extract wherein the amount of active compound is higher than in the natural extract, obtained by physical or chemical methods. The term "therapeutically effective amount" as used herein, refers to the amount of a compound that, when administered, is sufficient to prevent development of, alleviate to some extent, one or more of the symptons of the disorder, disease, microflora imbalance or condition being treated. The particular dose of compound administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and the similar considerations.
The term "saccharide" denotes saccharides epithelial cells receptor analog, for example methyl a mannoside, globotetraose, mannose, gal a(1 4) gal o linked methyl, sialyl 3' lactose, sialyl-gal (β 1 4)GlcNAc, oxidized( a1 6) glucan.
The term "epithelial cells" denotes herein to any epithelial cells which cover the external surface of the body as well as the major body cavities.
The term "probiotic" denotes live microorganisms which, when administered in adequate amounts, confer a health benefit on the host, and it has not modified its adhesion to the intestinal mucosa with the presence of the iminocyclitols. The term "(Ci-Cn)-alkyl"denotes herein straight or branched chain alkyl. The D-fagomine for the purposes of the invention can be synthetic or of natural origin, in the form of a plant extract or purified substance. The term "functional food" denotes herein any healthy food claimed to have a health-promoting or disease-preventing property beyond the basic function of supplying nutrients.
A particular embodiment is the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropiate edible salt thereof for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or repiratory bacteria. Preferably, the compounds of the invention are used in the prevention of a bacterial infection caused by an enteric, oral or respiratory bacteria.
In a particular embodiment the bacteria are selected from the group consisting of Streptococcus mutans, Salmonella tphimurium, Escherichia coli, Streptococcus mitis, Streptococcus oralis, Streptococcus gordonii,
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans,
Fusobacterium nucleatum and Actinomices naeslundii.
In a preferred embodiment, the compounds of the invention are used as coadjuvants in the treatment of a disease caused by the bacterial infection, which s selected from the group consisting of dental caries, periodontal disease, urinary disease, and intestinal disease.
In a preferred embodiment, the compounds of the invention are for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria, by inhibiting the adherence of enteric, oral or respiratory bacteria to epithelial cells.
By the term "bacterial adherence" is understood the process whereby bacteria attach themselves to cells or other surfaces before proliferating. As mentioned above a pharmaceutical composition or a veterinary
composition comprising the compounds of the invention or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof, together with
pharmaceutical or veterinary excipients or carriers also form part of the invention.
In a preferred embodiment the pharmaceutical composition is a mouthwash, a gel, a liquid dental cleaning lotion, a tooth paste, a chewing gum, a denture cleaner or a prothesis adherence cream. In a more preferred embodiment, the pharmaceutical composition is a chewing gum.
Furthermore, it is possible to use the compounds of the invention as part of a nutritional composition food, pet food and feedstuff. The said functional food has a positive effect on the person's or animal's health by preventing bacterial infection and microflora imbalances caused by an enteric, oral or respiratory bacteria. Relevant areas of use in feed as a preventive of diseases in animal production are for example salmonellosis in chicken production, harmful microbism reduction in pig to obtain a better growth, or acidosis prevention in ruminants.
The compounds of the invention can also be used as a food or a beverage additive to produce a functional food or a functional beverage. Thus, they can be added to liquid food products or concentrates or powders, such as milk and liquid milk like products, various beverage including juices, soft drinks, sport drinks, alcoholic beverages, and the like. It is specially useful to have the compound of the invention as part of a food for an infant, preferably as a part of a infant formula. It is also relevant the interest of functional food including buckweat with a remark on the content of D-fagomine, relevant examples could be beer, non-alcohol beer, tea like drink, milk like drink, pasta, biscuits, cookies, cereal bars, swollen grains, bread, crepes, cakes, creams, desserts, breakfast cereals and others that are enriched or
standarized in its basic D-fagomine content. Yoghourt and derivatives are also relevant foods to be used together with selected probiotics The food or food additive can also be produced in a natural way, e.g. by having a domestic animal such a cow or other animal that produce D- fagomine in its milk. This can be accomplished by feeding the animal with Fagopyrum esculentum, Moms alba or purified D-fagomine
Finally, as mentioned above the compounds of the invention may be used alone or in combination with other suitable bioactive compounds such as a saccharide, a iminocyclitol, probiotics or an antibacterial agent in prevention and /or coadjuvant treatment of a bacterial infection caused by an enteric, oral or respiratory bacteria. Pharmaceutical compositions, veterinary compositions food, pet food and feed products comprising the combination are also part of the invention. The combinations of the invention may be used in the prevention and/or coadjuvant treatment of a bacterial infection caused by enteric, oral or respiratory bacteria. Preferably, the combinations are used in the prevention and/or coadjuvant treatment of a bacterial infection caused by an enteric, oral or respiratory bacteria by inhibiting the adherence of enteric, oral or respiratory bacteria to epithelial cells. Preferably the combination is for sequential, simultaneous or separate administration.
Non limiting probiotics which may be used within the scope of the present invention are: Lactobacillus acidophilus, Lactobacillus rhamnosus,
Lactobacillus bulgaricus, Lactobacillus salivarius, Lactobacillus plantarum,
Lactobacillus casei, Lactobacillus sporogenes, Bifidobacteria bifidum,
Bifidobacteria longum, Bifidobacteria infantis
Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples are provided by way of illustration, and they are not intended to be limiting of the present invention. Furthermore, the present invention covers all possible
combinations of particular and preferred embodiments described herein. EXAMPLES
The following examples are provided for illustrative means, and are not meant to be limiting of the present invention.
Example 1 : Bacterial agglutination assay
Bacteria used in the assay were Escherichia coli. Salmonella tphimurium and Streptococcus mutans, from over night cultures. The bacteria were inoculated in the 100 ml flask with Luria medium. The bacteria were grown for 24 h at 37°C. After incubation, Agar Luria medium plates were inoculated. After 24h suspensions of each strain were prepared in PBS medium (108 CFU/ml).
Serial dilutions of the products to be tested, D-fagomine and D-fagomine tartrate (20 ppm, 200 ppm, 2000 ppm) were made. The dilutions were mixed with bacterial suspensions in a 1 :1 ratio. After 90 min. at room temperature the suspensions were observed under optical microscope. They were compared with the control culture without any product added. It was found that the two products assay at 20 ppm, 200 ppm and 2000 ppm, agglutinated the cells of the three strains.
When the bacteria are agglutinated they lost their ability to adhere to other cells or substrate.
Example 2: Bacterial agglutination assay Bacteria used in the assay were Escherichia coli, Salmonella tphimurium,
Streptococcus mutans, Lactobacillus casei and Bifidobacterium sp., from over night cultures. The bacteria were inoculated in the 100 ml flask with Luria medium. The bacteria were grown for 24 h at 37°C. After incubation, Agar Luria medium plates were inoculated. After 24h suspensions of each strain were prepared in PBS medium (108 CFU/ml). Serial dilutions of the product to be tested, D-fagomine tartrate (10 ppm, 20 ppm, 2000 ppm) were made. The dilutions were mixed with bacterial suspensions in a 1 :1 ratio. After 90 min. at room temperature the suspensions were observed under optical microscope. They were compared with the control culture without any product added. The Escherichia coli and Salmonella tphimurium were compared with a positive control culture (mannose 0,05M).
It was found that the product assay, at 20ppm and 200ppm, agglutinated the cells of the three strains, Escherichia coli, Salmonella tphimurium,
Streptococcus mutans, but not at 10ppm. When the concentration of the product assay is 20ppm, the agglutination was about 60% that of the corresponding positive control, and when the concentration is 200ppm was about 70%. Lactobacillus casei, Bifidobacterium sp were not agglutinated by D-fagomine tartrate. When the bacteria are agglutinated they lost their ability to adhere to other cells or substrate.
Example 3: Anti-adherence activity of D-fagomine against Streptococcus mutans
Glass surface adherence assay was performed. The bacterium used in the assay was Streptococcus mutans from over night cultures (1 1010 UCF/ml). The bacterium was grown for 18 h at 37°C in PBS medium. The bacteria from the overnight culture (0.25 ml) were grown for 18 h at 4°C in a glass dish with the specific medium (0.5 ml). After the 18 h, 0.25ml of D-fagomine (1 Oppm, 20ppm and 40ppm) was added. In the control plate was added only PBS. After 90 min. the cells were transfered (0.5ml) to a falcon tube, then were washed two times with PBS (0.5 ml each time). The wash of each bacteria was collected in a falcon tube and was kept at 4°C. The cells (100μΙ) were seeded in the plates in TSA medium. The cells adhered were scrapped.
In each well, it was added 0.5 ml of sterile PBS. The plaques with 100μΙ were inoculated. The plaques were counted.
Results: Table 1 . Results of the recounted from glass and supernatant.
Streptococcus mutans
Figure imgf000016_0001
Table 2. Results of the recounted from glass and supernatant.
Streptococcus mutans
Figure imgf000016_0002
G:glass S:supernatant
PG/CG: Product glass/Control glass(without product); colony forming units in glass by the action of D-fagomine or mannose 0.05M / colony forming units in glass without product
G/MG: Glass/ Mannose glass; colony forming units in glass by the action of D-fagomine or medium / colony forming units in glass by the action of mannose 0.05M
G/total; colony forming units in glass/total colony forming units inoculated. It was found that D-fagomine, at 10ppm, 20ppm and 40ppm, has
antiadherence activity in respect of the control.
Example 4: Adhesion of Salmonella and Escherichia colli to Mucus in D- fagomine presence
Mucus: mucosal epitelial cells
Adhesion to mucus. Protocol Day 1
The bacteria was inoculated in the tube, with 3 ml Luria medium. The bacteria were grown for 24 h at 37°C. The tube was incubated overnight (1 108-1 109 UCF/ml).
Mucus plate preparation
The mucus (1 ml) is defrosted at room temperature. PBS medium (100ml) was prepared. The defrosted mucus was centrifuged at 8000rpm for 10 minutes. The mucus (1 ml) was transferred to an aliquot with sterile PBS (99 ml) (1 :100). Each well is inoculated with 2,5 ml from the mixture and the plate is kept in the fridge (4°C) overnight.
Day 2
Mucus plate wash
The plate was taken out from the fridge. 2ml was extracted from each well. PBS (1 ml) was added, then was extracted, at the end there was 0.5 ml in the well.
Assay
The tubes that were grown overnight were diluted (1 107 UCF/ml).
The final volume in each well was: PBS 0.5 ml plus bacterial suspension 0.5 ml plus D-fagomine 0.5 ml (or PBS in control case).
Two plates were prepared (duplicated strains). Product concentration in the wells (10 ppm, 20 ppm, 40 pppm). Mannose concentration 0.05M ( control well).
The wells were inoculated and the plates were incubated at 37°C for 90 minutes. After the 90 minutes, the supernatant of each well (1 ΟμΙ) were observed under optical microscope.
It was added 1 ml of each well in eppendorfs. The eppendords were kept on the fridge. Two wash were made with PBS. The wells washed of the same strain were recoleted in a falcon tube and they were kept at 4°C. PBS (1 ml) was added in each well and the plates were inoculated with 100 μΙ of each tubes at the adecuated dilutions.
Day 3
The plates were recounted
Table3. Supernatant recounted with D-fagomine 10ppm, 20ppm, 40ppm
Figure imgf000018_0001
Table 4. Supernatant recounted with Mannose
Supernatant Mucus Supernatant/ Total Bacteria in (UCF/ml) UCF/ml mucus UCF/ml supernatant
UCF/ml (%)
Manose 0.05% Salmonella 3.95 108 1.00 106 3.59 102 3.96 108 99.7 mutans 1
Salmonella 3.74 108 1.50 107 2.49 10 3.89 108 96.1 mutans 2
Escherichia coli 2.98 108 2.50 106 1.19 102 3.01 108 99.2 I
Escherichia coli 2.96 108 2.45 106 1.21 102 2.98 108 99.2 2
Table 5. Supernatant recounted with culture medium
Figure imgf000019_0001
The microorganisms are significantly in the supernatant, not in the mucus. In the presence of D-fagomine the microorganisms are aglutinated between them and they are not agglutinated with the mucus, independently of the D- fagomine concentration.
Example 5: Adhesion of Lactobacillus and Bifidobacterium to Mucus in D- fagomine presence
Adhesion to mucus. Protocol
Day 1 The bacteria was inoculated in the tube with 3 ml Luria medium. The bacteria were grown for 24 h at 37°C. The tube was incubated overnight (1 107-1 108 UCF/ml).
Mucus plate preparation
The mucus (1 ml) is defrosted at room temperature. 100ml of PBS medium was prepared. The defrosted mucus (1 ml) was centrifuged at 8000rpm for 10 minutes. The mucus (1 ml) was transferred to an aliquot with sterile PBS (99 ml). Each well is inoculated with 2.5 ml from the mixture and the plate is kept in the fridge (4°C) overnight.
Day 2
Mucus plate wash
The plate was taken out from the fridge an the wash was made. 2ml was extracted from each well. PBS (1 ml) was added, then was extracted, at the end there was 0.5 ml in the well.
Assay
The tubes that were grown overnight, were diluted (1 107 UCF/ml).
The final volume in each well was: PBS 0.5 ml plus bacterial suspension 0.5 ml plus D-fagomine 0.5 ml (or PBS in control case). It was prepared 2 plates (duplicated strains). Product concentration in the wells (10 ppm, 20 ppm, 40 pppm). Mannose concentration 0.05M ( control well). The wells were inoculated and the plates were incubated at 37°C for 90 minutes. After the 90 minutes, the supernatant of each well (1 ΟμΙ) were observed under optical microscope. It was added 1 ml of each well in eppendorfs. The eppendords were kept on the fridge. Two wash were made with PBS. The wells washes of the same strain were recoleted in a falcon tube and they were kept at 4°C. PBS (1 ml) was added in each well and the plates were inoculated with 100 μΙ of each tubes at the adecuated dilutions.
Day 3
The plates were recounted
Results Table 6. Supernatant recounted with D-fagomine 10ppm, 20ppm, 40ppm, cultive medium and manose. Lactobacillus acidophilus
Figure imgf000021_0001
Table7. Supernatant recounted with D-fagomine 10ppm, 20ppm, 40ppm, cultive medium and manose. Bifidobacterium
Figure imgf000021_0002
Table8. Supernatant recounted with D-fagomine 10ppm, 20ppm, 40ppm,
Figure imgf000021_0003
M: Mucus, S: supernatant, Product, D fagomine or Mannose
Table9. Supernatant recounted with D-fagomine 10ppm, 20ppm, 40ppm, cultive medium and manose. Bifidobacterium
M/S Product M/Control M M/Manose M M/Total
10ppm 5.71 10~3 9.80 10~1 2.25 10~1 5.68 10~3 20ppm 6.67 10~3 1.14 2.62 10~1 2.00 10~2
40ppm 2.04 10~2 3.50 8.05 10~1 6.62 10~3
Cultive 5.83 10~3 2.30 10~1 5.80 10~3 medium
(Control)
Manose 2.85 10~2 4.35 1.86 10~2
0.05M
(Control)
M: Mucus, S: supernatant
D-fagomine does not interfere negatively the adherence of the Lactobacillus to the mucus. In view of the cultive medium results, the D-fagomine benefits the adherence of Lactobacillus to mucus.
D-fagomine does not interfere negatively the adherence of the Bifidobaterium to the mucus.

Claims

1 . A compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropriate edible salt thereof,
or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropriate edible salt thereof,
Figure imgf000023_0001
OR4
(I) wherein R-i, R2, R3 and R4 are independently selected from the group consisting of H, (CrCn)-alkyl, and CH2Ph, for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria.
2. The compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof or an appropriate edible salt thereof for use according to claim 1 .
3. The compound for use according to any of the claims 1 -2, wherein R-i, R2, R3 and R4 are H.
4. The compound for use according to any of the claims 1 -3, wherein the compound is used in the prevention of the bacterial infection.
5. The compound for use according claim 4, wherein the bacterial infection is caused by a bacteria selected from the group consisting of Streptococcus mutans, Salmonella tphimurium, and Escherichia coli.
6. The compound for use according to claim 4, wherein the bacterial infection causes a disease selected from the group consisting of dental disease, periodontal disease, urinary disease, and intestinal disease.
7. The compound for use according to any of the claims 1 -6, for use in the prevention and/or coadjuvant treatment of a bacterial infection or microflora imbalance caused by an enteric, oral or respiratory bacteria, by inhibiting the adherence of enteric, oral or respiratory bacteria to epithelial cells.
8. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in any of the claims 1 -3, together with pharmaceutical excipients or carriers.
9. The pharmaceutical composition according to claim 8, which is a
mouthwash, a gel, a liquid dental cleaning lotion, a tooth paste, a chewing gum, a denture cleaner, or a prosthesis adherence cream.
10. A veterinary composition comprising a compound of formula (I) or a veterinary acceptable salt thereof, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a veterinary acceptable salt thereof, as defined in any of the claims 1 -3, together with veterinary excipients or carriers.
1 1 . A food composition, a feed composition or a pet food composition comprising a compound of formula (I) or an appropriate edible salt thereof, or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a edible acceptable salt thereof.
12. A combination of a compound of formula (I) or an appropriate pharmaceutically, veterinary or edible acceptable salt thereof, or
alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt 5 thereof or an appropriate edible salt thereof, as defined in any of the claims 1 - 3, with a saccharide, a iminocyclitol, probiotics or an antibacterial agent, for use in the prevention and/or coadjuvant treatment of a bacterial infection caused by an enteric, oral or respiratory bacteria. 0 13. The combination for use according to claim 12, for use in the prevention and/or coadjuvant treatment of a bacterial infection caused by an enteric, oral or respiratory bacteria, by inhibiting the adherence of enteric, oral or respiratory bacteria to epithelial cells. 5
14. The combination for use according to any of the claims 1 1 -12, wherein the combination is for sequential, simultaneous, or separate administration.
15. A pharmaceutical or veterinary composition , comprising a combination of a compound of formula (I) or an appropriate pharmaceutically, or veterinary o acceptable salt thereof or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a veterinary salt thereof,as defined in any of the claims 1 -3, with a saccharide, a iminocyclitol, probiotics or an antibacterial agent, together with pharmaceutical or veterinary excipients or carriers.
5
16. A food, pet food or feed composition comprising a combination of a compound of formula (I) or an edible acceptable salt thereof or alternatively, an enriched extract of natural origin comprising a compound of formula (I) or a edibe salt thereof as defined in any of the claims 1 -3, with a saccharide a0 iminocyclitol, or probiotics.
PCT/EP2011/054561 2010-03-25 2011-03-24 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells WO2011117362A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MX2012010988A MX2012010988A (en) 2010-03-25 2011-03-24 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells.
PL11710197T PL2549994T3 (en) 2010-03-25 2011-03-24 Use of d-fagomine as inhibitor of bacterial adherence to epithelial cells
EP11710197.2A EP2549994B1 (en) 2010-03-25 2011-03-24 Use of d-fagomine as inhibitor of bacterial adherence to epithelial cells
US13/636,155 US9226517B2 (en) 2010-03-25 2011-03-24 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells
DK11710197.2T DK2549994T3 (en) 2010-03-25 2011-03-24 Use of D-phagomin as an inhibitor of bacterial adhesion to epithelial cells
ES11710197.2T ES2551408T3 (en) 2010-03-25 2011-03-24 Use of d-fagomin as an inhibitor of bacterial adhesion to epithelial cells
CN2011800154714A CN102811720A (en) 2010-03-25 2011-03-24 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382068.4 2010-03-25
EP10382068 2010-03-25

Publications (1)

Publication Number Publication Date
WO2011117362A1 true WO2011117362A1 (en) 2011-09-29

Family

ID=42225075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/054561 WO2011117362A1 (en) 2010-03-25 2011-03-24 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells

Country Status (8)

Country Link
US (1) US9226517B2 (en)
EP (1) EP2549994B1 (en)
CN (1) CN102811720A (en)
DK (1) DK2549994T3 (en)
ES (1) ES2551408T3 (en)
MX (1) MX2012010988A (en)
PL (1) PL2549994T3 (en)
WO (1) WO2011117362A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767284A1 (en) 2013-02-18 2014-08-20 Bioglane, S.L. D-Fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987316B2 (en) 2012-09-14 2018-06-05 Case Western Reserve University Probiotic controlling fungi and uses thereof
CN103431180A (en) * 2013-09-03 2013-12-11 湖北省农业科学院经济作物研究所 Preparation method of mulberry leaf feed
WO2017131691A1 (en) 2016-01-28 2017-08-03 Kimberly-Clark Worldwide, Inc. Anti-adherent composition against dna viruses and method of inhibiting the adherence of dna viruses to a surface
MX2018013276A (en) 2016-05-26 2019-03-28 Kimberly Clark Co Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface.
CN107382826B (en) * 2017-08-09 2020-01-14 江苏中兴药业有限公司 Fagopyrine in wild buckwheat rhizome and content determination method thereof
WO2021132441A1 (en) * 2019-12-27 2021-07-01 サントリーホールディングス株式会社 Green tea beverage having reduced off-flavor
JP6808082B1 (en) * 2019-12-27 2021-01-06 サントリーホールディングス株式会社 Green tea beverage with enhanced bitterness

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271085A (en) * 1992-03-30 1993-10-19 Sunstar Inc Agent for preventing periodontosis
EP0852948A1 (en) 1997-01-08 1998-07-15 University College London Use of glycosidase inhibitor for the preparation of a medicament for the prophylaxis or treatment of malaria, endotoxic shock or septic shock
WO2003002127A1 (en) 2001-06-29 2003-01-09 Glykos Finland Oy Use of at least one glycoinhibitor substance
JP2007230719A (en) 2006-02-28 2007-09-13 Mec:Kk Tension applying device
CA2696874A1 (en) 2006-08-21 2008-03-06 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences The use of the effective fraction of alkaloids from mulberry twig in preparing hypoglycemic agents
JP2009062306A (en) * 2007-09-05 2009-03-26 Iwate Univ Immunopotentiator
US20090087501A1 (en) 2007-10-01 2009-04-02 Colgate-Palmolive Company Oral Compositions Containing Botanical Extracts
WO2009152665A1 (en) 2008-06-20 2009-12-23 湖南希尔天然药业有限公司 A pharmaceutical composition for treating diabetes
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271085A (en) * 1992-03-30 1993-10-19 Sunstar Inc Agent for preventing periodontosis
EP0852948A1 (en) 1997-01-08 1998-07-15 University College London Use of glycosidase inhibitor for the preparation of a medicament for the prophylaxis or treatment of malaria, endotoxic shock or septic shock
WO2003002127A1 (en) 2001-06-29 2003-01-09 Glykos Finland Oy Use of at least one glycoinhibitor substance
JP2007230719A (en) 2006-02-28 2007-09-13 Mec:Kk Tension applying device
CA2696874A1 (en) 2006-08-21 2008-03-06 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences The use of the effective fraction of alkaloids from mulberry twig in preparing hypoglycemic agents
JP2009062306A (en) * 2007-09-05 2009-03-26 Iwate Univ Immunopotentiator
US20090087501A1 (en) 2007-10-01 2009-04-02 Colgate-Palmolive Company Oral Compositions Containing Botanical Extracts
WO2009152665A1 (en) 2008-06-20 2009-12-23 湖南希尔天然药业有限公司 A pharmaceutical composition for treating diabetes
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ASANO ET AL.: "N-containing sugars from Morus Alba and their glycosidase inhibitory activities", CARBOHYDRATE RESEARCH, vol. 259, 1994, pages 243 - 255, XP026730658, DOI: doi:10.1016/0008-6215(94)84060-1
ASANO N ET AL: "N-containing sugars fromMorus alba and their glycosidase inhibitory activities", CARBOHYDRATE RESEARCH, PERGAMON, GB LNKD- DOI:10.1016/0008-6215(94)84060-1, vol. 259, no. 2, 17 June 1994 (1994-06-17), pages 243 - 255, XP026730658, ISSN: 0008-6215, [retrieved on 19940617] *
BARIRA ISLAM ET AL.: "Novel anti-adherence activity of mulberry leaves: Inhibition of Streptococcus mutans biofilm by 1-deoxynojirimycin isolated from Morus alba", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 62, 2008, pages 751 - 757, XP055165512, DOI: doi:10.1093/jac/dkn253
CASTILLO ET AL.: "Supporting Information : Fructose-6-phosphate aldolase in organic synthesis: Preparation of d-fagomine, N-alkylated derivatives, and preliminary biological assays", ORGANIC LETTERS, 29 November 2006 (2006-11-29), pages S1 - S29, XP002587180, Retrieved from the Internet <URL:http://pubs.acs.org/doi/suppl/10.1021/ol0625482/suppl_file/ol0625482si20061017_054337.pdf> [retrieved on 20100610] *
CASTILLO ET AL: "Fructose-6-phosphate aldolase in organic synthesis: Preparation of d-fagomine, N-alkylated derivatives, and preliminary biological assays", ORGANIC LETTERS, AMERICAN CHEMICAL SOCIETY, US LNKD- DOI:10.1021/OL0625482, vol. 8, 29 November 2006 (2006-11-29), pages 6067 - 6070, XP002461275, ISSN: 1523-7060 *
DATABASE WPI Week 199346, Derwent World Patents Index; AN 1993-365152, XP002587181, "Gum disease prevention agents - comprise extracts obtd. from specified plants and are used in mouth wash, tooth-paste, etc." *
DATABASE WPI Week 200924, Derwent World Patents Index; AN 2009-G26372, XP002587182, "Immunostimulant useful as pharmaceuticals, quasi-drug or food/beverage products for preventing and/or treating cancer and infectious disease caused by bacteria and viruses, comprises water-soluble extract of mulberry bark" *
JOSE A. CASTILLO: "Fructose-6-phosphate aldolase in organic synthesis: preparation of D- Fagomine, N-alkylated derivatives, and preliminary biological assays", ORGANIC LETTER, vol. 8, no. 26, 2006, pages 6067 - 6070
OFEK ET AL.: "Bacterial adhesion to animal cells and tissues", 2003, ASM PRESS
SHARON ET AL.: "Bacterial adherence to cell surface sugars", CIBA FOUND SYMP, vol. 80, 1981, pages 119 - 41

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767284A1 (en) 2013-02-18 2014-08-20 Bioglane, S.L. D-Fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response
WO2014125013A1 (en) 2013-02-18 2014-08-21 Bioglane, S.L.N.E. D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response
US20150368283A1 (en) * 2013-02-18 2015-12-24 Sergio Pumarola Segura D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response
EA030688B1 (en) * 2013-02-18 2018-09-28 Серхио Пумарола Сегура Use of d-fagomine as an immunostimulating agent of innate immune system at a mucosal level and for the control of inflammatory processes related to an overactivation of the humoral immune response
US10233206B2 (en) 2013-02-18 2019-03-19 Sergio Pumarola Segura D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response

Also Published As

Publication number Publication date
PL2549994T3 (en) 2016-06-30
EP2549994B1 (en) 2015-08-05
ES2551408T3 (en) 2015-11-18
US20130011344A1 (en) 2013-01-10
CN102811720A (en) 2012-12-05
MX2012010988A (en) 2012-10-15
US9226517B2 (en) 2016-01-05
DK2549994T3 (en) 2015-11-09
EP2549994A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
US9226517B2 (en) Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells
US20050129629A1 (en) Use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
KR101900992B1 (en) Prophylactic or therapeutic agent for oral diseases
KR101768678B1 (en) Bifidobacterium longum ssp. infantis BI9988 isolated from Korean longevity village and having high nutraceutical activities
DE60003515T2 (en) BEVERAGES AND FOODS SUITED TO ELIMINATE HELICOBACTER PYLORI
US20030157079A1 (en) Lactic acid bacteria-containing probiotics products
WO2021177526A1 (en) Breast milk-derived lactobacillus reuteri lm1071 strain having excellent safety and intestinal adhesiveness, and composition comprising strain or cultured product thereof
JPWO2002080946A1 (en) Composition for prevention and / or treatment of oral disease
KR102001074B1 (en) Lactobacillus having anticariogenic activities and composition comprising the same
EP2710901A1 (en) Dietary supplement compositions
JP2016513631A (en) Lactobacillus plantarum NCC2936 preparation and oral health
JP4440095B2 (en) Anti-periodontal disease bacteria composition
JP2001512670A (en) New lactic acid bacteria
JP4846643B2 (en) New lactic acid bacteria
KR101488770B1 (en) Lactobacillus fermentum PL9036 isolated from healthy senior citizens in the Korean longevity villages
KR102421144B1 (en) Bifidobacterium bifidum EPS DA-LAIM promoting the growth of lactobacillus and polysaccharide therefrom
JP4982636B2 (en) Cavity prevention composition
KR102511133B1 (en) Composition for Inhibiting Biofilm Formation Comprising Extracts of Coptis chinensis
KR102217518B1 (en) Probiotics for prevention or treatment of periodontitis and use thereof
KR20230152489A (en) Composition for improving intestinal health for infant and pregnant
CN115671143A (en) Use of cultures of lactic acid bacterial strains for inhibiting growth of oral pathogenic bacteria and for preventing and/or treating diseases associated with oral pathogenic bacteria

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180015471.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11710197

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13636155

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/010988

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011710197

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012023786

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112012023786

Country of ref document: BR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: 112012023786

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO TER CUMPRIDO EXIGENCIA FORMULADA NA RPI NO 2439, DE 03/10/2017.

Ref document number: 112012023786

Country of ref document: BR